207
Participants
Start Date
October 3, 2018
Primary Completion Date
December 30, 2019
Study Completion Date
January 30, 2020
300mg netupitant/0.5mg palonosetron hydrochloride
Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
Tom Baker Cancer Center, Calgary
The Moncton Hospital, Moncton
NSHA-QEII Health Sciences Centre, Halifax
Cape Breton Cancer Centre, Sydney
Royal Victoria Regional Health Centre, Barrie
William Osler Health System, Brampton
Grand River Regional Cancer Centre, Kitchener
London Health Sciences Centre, London
Thunder Bay Regional Health Sciences Centre, Thunder Bay
St. Michael's Hospital, Toronto
Sunnybrook Health Sciences Center, Toronto
Windsor Regional Cancer Centre, Windsor
Centre Integre de Sante et de Services Sociaux de la Monteregie-Centre, Greenfield Park
Cisss de Chaudiere-Appalaches, Lévis
Segal Cancer Centre-Jewish General Hospital, Montreal
Centre de recherche du CHUS and Hopital Fleurimont, Sherbrooke
Saskatoon Cancer Centre, Saskatoon
Purdue Pharma, Canada
INDUSTRY